{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:55:43Z","timestamp":1793451343732,"version":"4.5.0"},"reference-count":197,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Diabetes is common in patients waitlisted for liver transplantation because of end-stage liver disease or hepatocellular cancer as well as in posttransplant phase (posttransplantation diabetes mellitus). In both conditions, the presence of diabetes severely affects disease burden and long-term clinical outcomes; careful monitoring and appropriate treatment are pivotal to reduce cardiovascular events and graft and recipients\u2019 death. We thoroughly reviewed the epidemiology of diabetes in the transplant setting and the different therapeutic options, from lifestyle intervention to antidiabetic drug use\u2014including the most recent drug classes available\u2014and to the inclusion of bariatric surgery in the treatment cascade. In waitlisted patients, the old paradigm that insulin should be the treatment of choice in the presence of severe liver dysfunction is no longer valid; novel antidiabetic agents may provide adequate glucose control without the risk of hypoglycemia, also offering cardiovascular protection. The same evidence applies to the posttransplant phase, where oral or injectable noninsulin agents should be considered to treat patients to target, limiting the impact of disease on daily living, without interaction with immunosuppressive regimens. The increasing prevalence of liver disease of metabolic origin (nonalcoholic fatty liver) among liver transplant candidates, also having a higher risk of noncirrhotic hepatocellular cancer, is likely to accelerate the acceptance of new drugs and invasive procedures, as suggested by international guidelines. Intensive lifestyle intervention programs remain however mandatory, both before and after transplantation. Achievement of adequate control is mandatory to increase candidacy, to prevent delisting, and to improve long-term outcomes.<\/jats:p>","DOI":"10.1097\/tp.0000000000003867","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:09:34Z","timestamp":1624666174000},"page":"462-478","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":33,"title":["Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients"],"prefix":"10.1097","volume":"106","author":[{"given":"Lucia","family":"Brodosi","sequence":"first","affiliation":[{"name":"IRCCS \u2013 Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy."},{"name":"Department of Medical and Surgical Sciences, Alma Mater University, Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Petroni","sequence":"additional","affiliation":[{"name":"IRCCS \u2013 Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy."},{"name":"Department of Medical and Surgical Sciences, Alma Mater University, Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Marchesini","sequence":"additional","affiliation":[{"name":"IRCCS \u2013 Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy."},{"name":"Department of Medical and Surgical Sciences, Alma Mater University, Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Morelli","sequence":"additional","affiliation":[{"name":"IRCCS \u2013 Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11892-015-0707-1","article-title":"Hyperglycemia and diabetes mellitus following organ transplantation.","volume":"16","author":"Galindo","year":"2016","journal-title":"Curr Diab Rep"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions.","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transplant"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes\u20142021.","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc21-S006","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes\u20142021.","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.2337\/dc21-S012","article-title":"12. Older adults: Standards of Medical Care in Diabetes\u20142021.","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/hep.26972","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.","volume":"59","author":"Martin","year":"2014","journal-title":"Hepatology"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL Clinical Practice Guidelines: liver transplantation.","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/flgastro-2019-101215","article-title":"Adult liver transplantation: a UK clinical guideline\u2014part 1: pre-operation.","volume":"11","author":"Millson","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/flgastro-2019-101216","article-title":"Adult liver transplantation: UK clinical guideline\u2014part 2: surgery and post-operation.","volume":"11","author":"Millson","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000002433","article-title":"International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation.","volume":"103","author":"Tsochatzis","year":"2019","journal-title":"Transplantation"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0000000000002507","article-title":"The ILTS Consensus Conference on NAFLD\/NASH and Liver Transplantation: setting the stage.","volume":"103","author":"Burra","year":"2019","journal-title":"Transplantation"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations.","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1399-0012.2005.00359.x","article-title":"Guidelines for the treatment and management of new-onset diabetes after transplantation.","volume":"19","author":"Wilkinson","year":"2005","journal-title":"Clin Transplant"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden.","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jhep.2018.02.004","article-title":"Recipient characteristics and morbidity and mortality after liver transplantation.","volume":"69","author":"Asrani","year":"2018","journal-title":"J Hepatol"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cgh.2013.09.023","article-title":"Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis.","volume":"12","author":"Wang","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/lt.25863","article-title":"Outcomes of liver transplantation among older recipients with nonalcoholic steatohepatitis in a large multicenter US cohort: the re-evaluating age limits in transplantation consortium.","volume":"26","author":"Kwong","year":"2020","journal-title":"Liver Transpl"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","article-title":"Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases.","volume":"61","author":"Negro","year":"2014","journal-title":"J Hepatol"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/liv.13337","article-title":"Hepatogenous diabetes: is it time to separate it from type 2 diabetes?","volume":"37","author":"Orsi","year":"2017","journal-title":"Liver Int"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jhep.2019.01.015","article-title":"Central role of the \u03b2-cell in driving regression of diabetes after liver transplantation in cirrhotic patients.","volume":"70","author":"Grancini","year":"2019","journal-title":"J Hepatol"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1467-789x.2000.00013.x","article-title":"Redefining type 2 diabetes: \u2018diabesity\u2019 or \u2018obesity dependent diabetes mellitus\u2019?","volume":"1","author":"Astrup","year":"2000","journal-title":"Obes Rev"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States.","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.","volume":"69","author":"Belli","year":"2018","journal-title":"J Hepatol"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/hep.26886","article-title":"Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis.","volume":"59","author":"De Souza","year":"2014","journal-title":"Hepatology"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/lt.22128","article-title":"Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score.","volume":"16","author":"Francoz","year":"2010","journal-title":"Liver Transpl"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142021.","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1753-0407.12524","article-title":"American Diabetes Association Standards of Medical Care in Diabetes 2017.","volume":"9","author":"Marathe","year":"2017","journal-title":"J Diabetes"},{"key":"R32-20250607","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.dld.2016.12.028","article-title":"Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?","volume":"49","author":"Mazzotti","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R33-20250607","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk.","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"R34-20250607","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/TP.0000000000002175","article-title":"Cardiovascular disease outcomes related to early stage renal impairment after liver transplantation.","volume":"102","author":"VanWagner","year":"2018","journal-title":"Transplantation"},{"key":"R35-20250607","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ.","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R36-20250607","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/11536790-000000000-00000","article-title":"Lactic acidosis induced by metformin: incidence, management and prevention.","volume":"33","author":"Lalau","year":"2010","journal-title":"Drug Saf"},{"key":"R37-20250607","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/17425255.2013.777428","article-title":"Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.","volume":"9","author":"Scheen","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R38-20250607","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4.","volume":"41","author":"Lalau","year":"2018","journal-title":"Diabetes Care"},{"key":"R39-20250607","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/17425255.2014.902444","article-title":"Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.","volume":"10","author":"Scheen","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R40-20250607","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"key":"R41-20250607","doi-asserted-by":"crossref","first-page":"e49279","DOI":"10.1371\/journal.pone.0049279","article-title":"Metformin inhibits glutaminase activity and protects against hepatic encephalopathy.","volume":"7","author":"Ampuero","year":"2012","journal-title":"PLoS One"},{"key":"R42-20250607","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fendo.2019.00617","article-title":"The potential effect of metformin on cancer: an umbrella review.","volume":"10","author":"Yu","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R43-20250607","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"97","author":"Zhang","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20250607","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/jc.2010-2415","article-title":"Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.","volume":"96","author":"Nkontchou","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R45-20250607","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.beem.2007.09.004","article-title":"PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.","volume":"21","author":"Gross","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R46-20250607","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis.","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"suppl 1","key":"R47-20250607","article-title":"223-OR: pioglitazone discontinuation in patients with nonalcoholic steatohepatitis (NASH) is associated with disease recurrence.","volume":"68","author":"Bril","year":"2019","journal-title":"Diabetes"},{"key":"R48-20250607","doi-asserted-by":"crossref","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","article-title":"Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"key":"R49-20250607","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"R50-20250607","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack.","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"R51-20250607","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc11-2197","article-title":"Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study.","volume":"36","author":"Chen","year":"2013","journal-title":"Diabetes Care"},{"key":"R52-20250607","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/hep.25509","article-title":"Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.","volume":"55","author":"Chang","year":"2012","journal-title":"Hepatology"},{"key":"R53-20250607","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198106030-00003","article-title":"Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs.","volume":"6","author":"Balant","year":"1981","journal-title":"Clin Pharmacokinet"},{"key":"R54-20250607","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14740338.2012.694424","article-title":"Drug-induced hypoglycaemia in type 2 diabetes.","volume":"11","author":"Inkster","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"R55-20250607","doi-asserted-by":"crossref","first-page":"e186125","DOI":"10.1001\/jamanetworkopen.2018.6125","article-title":"Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes.","volume":"1","author":"O\u2019Brien","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R56-20250607","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1463-1326.2001.00103.x","article-title":"Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis.","volume":"3","author":"Gentile","year":"2001","journal-title":"Diabetes Obes Metab"},{"key":"R57-20250607","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1542-3565(04)00667-6","article-title":"A randomized controlled trial of acarbose in hepatic encephalopathy.","volume":"3","author":"Gentile","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R58-20250607","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.regpep.2004.06.001","article-title":"Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?","volume":"128","author":"McIntosh","year":"2005","journal-title":"Regul Pept"},{"key":"R59-20250607","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"key":"R60-20250607","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF03261927","article-title":"Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.","volume":"51","author":"Golightly","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"R61-20250607","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40262-014-0157-y","article-title":"Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R62-20250607","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/22123911MTA5pMzA20","article-title":"Efficacy and cardiovascular safety of DPP-4 inhibitors.","volume":"16","author":"Subrahmanyan","year":"2021","journal-title":"Curr Drug Saf"},{"key":"R63-20250607","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","article-title":"Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.","volume":"18","author":"Fei","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R64-20250607","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-019-0853-x","article-title":"Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.","volume":"18","author":"Yang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R65-20250607","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000454683","article-title":"Dipeptidyl peptidase-4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials.","volume":"136","author":"Walker","year":"2017","journal-title":"Nephron"},{"key":"R66-20250607","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"R67-20250607","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/dom.14008","article-title":"Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.","volume":"22","author":"Hussein","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R68-20250607","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/hep.30670","article-title":"Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes.","volume":"69","author":"Cusi","year":"2019","journal-title":"Hepatology"},{"key":"R69-20250607","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14712598.2017.1296131","article-title":"Dulaglutide for the treatment of type 2 diabetes.","volume":"17","author":"Scheen","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"R70-20250607","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03762.x","article-title":"Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.","volume":"70","author":"Flint","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R71-20250607","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R72-20250607","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"R73-20250607","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"R74-20250607","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/oby.2011.152","article-title":"Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.","volume":"19","author":"Sathyanarayana","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"R75-20250607","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"R76-20250607","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet Med"},{"key":"R77-20250607","doi-asserted-by":"crossref","first-page":"e005325","DOI":"10.1136\/bmjopen-2014-005325","article-title":"Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes.","volume":"4","author":"Gluud","year":"2014","journal-title":"BMJ Open"},{"key":"R78-20250607","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/liv.14799","article-title":"Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: a real-world data analysis.","volume":"41","author":"Colosimo","year":"2021","journal-title":"Liver Int"},{"key":"R79-20250607","doi-asserted-by":"crossref","first-page":"e00082","DOI":"10.1002\/edm2.82","article-title":"Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: a retrospective cohort study.","volume":"2","author":"Petroni","year":"2019","journal-title":"Endocrinol Diab Metab"},{"key":"R80-20250607","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"R81-20250607","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R82-20250607","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/L20-0041","article-title":"The effect of liraglutide on \u03b2-blockade for preventing variceal bleeding: a case series.","volume":"173","author":"Vukotic","year":"2020","journal-title":"Ann Intern Med"},{"key":"R83-20250607","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clinthera.2014.12.013","article-title":"Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.","volume":"37","author":"Devineni","year":"2015","journal-title":"Clin Ther"},{"key":"R84-20250607","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.clinthera.2011.09.011","article-title":"Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.","volume":"33","author":"Kasichayanula","year":"2011","journal-title":"Clin Ther"},{"key":"R85-20250607","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/dom.12183","article-title":"Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.","volume":"16","author":"Macha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R86-20250607","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites.","volume":"11","author":"Saffo","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"R87-20250607","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R88-20250607","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial).","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"R89-20250607","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R90-20250607","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population.","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"R91-20250607","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest.","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"R92-20250607","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2019.01.001","article-title":"Effects of sodium-glucose cotransporter 2 inhibitor monotherapy on weight changes in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis.","volume":"41","author":"Wang","year":"2019","journal-title":"Clin Ther"},{"key":"R93-20250607","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R94-20250607","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/dom.13620","article-title":"The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis.","volume":"21","author":"Wang","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R95-20250607","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R96-20250607","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"R97-20250607","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.numecd.2017.10.008","article-title":"Adverse events with sodium-glucose co-transporter-2 inhibitors: a global analysis of international spontaneous reporting systems.","volume":"27","author":"Raschi","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R98-20250607","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"key":"R99-20250607","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"key":"R100-20250607","first-page":"1263","article-title":"Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients.","volume":"77","author":"Letiexhe","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R101-20250607","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1463-1326.2007.00802.x","article-title":"Insulin therapy in renal disease.","volume":"10","author":"Iglesias","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"R102-20250607","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1525-139X.2010.00703.x","article-title":"Selection and dosing of medications for management of diabetes in patients with advanced kidney disease.","volume":"23","author":"Reilly","year":"2010","journal-title":"Semin Dial"},{"key":"R103-20250607","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2337\/diacare.25.1.35","article-title":"The network of psychological variables in patients with diabetes and their importance for quality of life and metabolic control.","volume":"25","author":"Rose","year":"2002","journal-title":"Diabetes Care"},{"key":"R104-20250607","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2 diabetes.","volume":"4","author":"Garc\u00eda-P\u00e9rez","year":"2013","journal-title":"Diabetes Ther"},{"key":"R105-20250607","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1185\/03007990903421994","article-title":"Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.","volume":"26","author":"Cooke","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R106-20250607","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40618-016-0508-7","article-title":"Insulin, insulin receptors, and cancer.","volume":"39","author":"Vigneri","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"R107-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MEG.0000000000001001","article-title":"Association between insulin therapy and risk of liver cancer among diabetics: a meta-analysis of epidemiological studies.","volume":"30","author":"Liu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R108-20250607","doi-asserted-by":"crossref","first-page":"e3082","DOI":"10.1002\/dmrr.3082","article-title":"GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis.","volume":"35","author":"Castellana","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"R109-20250607","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2337\/diacare.25.12.2165","article-title":"The Diabetes Prevention Program (DPP): description of lifestyle intervention.","volume":"25","year":"2002","journal-title":"Diabetes Care"},{"key":"R110-20250607","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"R111-20250607","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial.","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"key":"R112-20250607","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"R113-20250607","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4254\/wjh.v4.i7.224","article-title":"Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China.","volume":"4","author":"Sun","year":"2012","journal-title":"World J Hepatol"},{"key":"R114-20250607","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study.","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology"},{"key":"R115-20250607","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jhep.2018.07.013","article-title":"An internet-based approach for lifestyle changes in patients with NAFLD: two-year effects on weight loss and surrogate markers.","volume":"69","author":"Mazzotti","year":"2018","journal-title":"J Hepatol"},{"key":"R116-20250607","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/dom.13007","article-title":"Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial.","volume":"19","author":"Khoo","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R117-20250607","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int"},{"key":"R118-20250607","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients.","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"R119-20250607","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/SLA.0000000000000945","article-title":"Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study.","volume":"260","author":"Caiazzo","year":"2014","journal-title":"Ann Surg"},{"key":"R120-20250607","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/SLA.0000000000003871","article-title":"Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: a retrospective cohort analysis.","volume":"272","author":"Wirth","year":"2020","journal-title":"Ann Surg"},{"key":"R121-20250607","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1001\/jama.2014.5988","article-title":"Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.","volume":"311","author":"Sj\u00f6str\u00f6m","year":"2014","journal-title":"JAMA"},{"key":"R122-20250607","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet"},{"key":"R123-20250607","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1470-2045(09)70159-7","article-title":"Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial.","volume":"10","author":"Sj\u00f6str\u00f6m","year":"2009","journal-title":"Lancet Oncol"},{"key":"R124-20250607","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric surgery and long-term cardiovascular events.","volume":"307","author":"Sj\u00f6str\u00f6m","year":"2012","journal-title":"JAMA"},{"key":"R125-20250607","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cgh.2011.07.007","article-title":"Increased perioperative mortality following bariatric surgery among patients with cirrhosis.","volume":"9","author":"Mosko","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R126-20250607","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.soard.2013.02.013","article-title":"Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates.","volume":"9","author":"Lin","year":"2013","journal-title":"Surg Obes Relat Dis"},{"key":"R127-20250607","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.3748\/wjg.v24.i28.3112","article-title":"Considerations for bariatric surgery in patients with cirrhosis.","volume":"24","author":"Goh","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R128-20250607","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.soard.2007.12.009","article-title":"Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation.","volume":"4","author":"Takata","year":"2008","journal-title":"Surg Obes Relat Dis"},{"key":"R129-20250607","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/lt.25368","article-title":"Impact of prior bariatric surgery on perioperative liver transplant outcomes.","volume":"25","author":"Idriss","year":"2019","journal-title":"Liver Transpl"},{"key":"R130-20250607","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1111\/ajt.16583","article-title":"Sleeve gastrectomy prior to liver transplantation is superior to medical weight loss in reducing post-transplant metabolic complications.","volume":"21","author":"Sharpton","year":"2021","journal-title":"Am J Transplant"},{"key":"R131-20250607","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1600-6143.2012.04318.x","article-title":"Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease.","volume":"13","author":"Heimbach","year":"2013","journal-title":"Am J Transplant"},{"key":"R132-20250607","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s11695-017-2634-5","article-title":"Simultaneous liver transplantation and sleeve gastrectomy: prohibitive combination or a necessity?","volume":"27","author":"Nesher","year":"2017","journal-title":"Obes Surg"},{"key":"R133-20250607","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11695-017-2847-7","article-title":"Laparoscopic sleeve gastrectomy for morbid obesity in patients after orthotopic liver transplant: a matched case-control study.","volume":"28","author":"Tsamalaidze","year":"2018","journal-title":"Obes Surg"},{"key":"R134-20250607","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.soard.2020.05.012","article-title":"Bariatric surgery before, during, and after liver transplantation: a systematic review and meta-analysis.","volume":"16","author":"Lee","year":"2020","journal-title":"Surg Obes Relat Dis"},{"key":"R135-20250607","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s11695-020-05118-7","article-title":"Are we ready for bariatric surgery in a liver transplant program? a meta-analysis.","volume":"31","author":"Lopez-Lopez","year":"2021","journal-title":"Obes Surg"},{"key":"R136-20250607","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/cc12514","article-title":"Stress hyperglycemia: an essential survival response!","volume":"17","author":"Marik","year":"2013","journal-title":"Crit Care"},{"key":"R137-20250607","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/S0140-6736(09)60553-5","article-title":"Stress hyperglycaemia.","volume":"373","author":"Dungan","year":"2009","journal-title":"Lancet"},{"key":"R138-20250607","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41574-018-0137-7","article-title":"Post-transplant diabetes mellitus in patients with solid organ transplants.","volume":"15","author":"Jenssen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"R139-20250607","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jcem.87.3.8341","article-title":"Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.","volume":"87","author":"Umpierrez","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R140-20250607","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jdiacomp.2014.03.008","article-title":"Inpatient dysglycemia and clinical outcomes: association or causation?","volume":"28","author":"Umpierrez","year":"2014","journal-title":"J Diabetes Complications"},{"key":"R141-20250607","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.2337\/dc21-S015","article-title":"15. Diabetes care in the hospital: Standards of Medical Care in Diabetes\u20142021.","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R143-20250607","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2337\/dc15-2383","article-title":"GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes.","volume":"39","author":"Halden","year":"2016","journal-title":"Diabetes Care"},{"key":"R144-20250607","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s11605-015-2832-1","article-title":"Donor hepatic steatosis and outcome after liver transplantation: a systematic review.","volume":"19","author":"Chu","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"R145-20250607","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/01.tp.0000250361.60415.96","article-title":"Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up.","volume":"82","author":"Moon","year":"2006","journal-title":"Transplantation"},{"key":"R146-20250607","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transplant"},{"key":"R147-20250607","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12881","article-title":"The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US.","volume":"40","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R148-20250607","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/1753-0407.12275","article-title":"New-onset diabetes after liver transplantation and its impact on complications and patient survival.","volume":"7","author":"Lv","year":"2015","journal-title":"J Diabetes"},{"key":"R149-20250607","doi-asserted-by":"crossref","first-page":"e3829","DOI":"10.1097\/MD.0000000000003829","article-title":"Prevalence, predictive factors, and survival outcome of new-onset diabetes after liver transplantation: a population-based cohort study.","volume":"95","author":"Liu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R150-20250607","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/ajt.14401","article-title":"Sustained posttransplantation diabetes is associated with long-term major cardiovascular events following liver transplantation.","volume":"18","author":"Roccaro","year":"2018","journal-title":"Am J Transplant"},{"key":"R151-20250607","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.mayocp.2018.06.020","article-title":"New-onset diabetes and preexisting diabetes are associated with comparable reduction in long-term survival after liver transplant: a machine learning approach.","volume":"93","author":"Bhat","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"R152-20250607","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1097\/TP.0000000000002757","article-title":"The impact of preexisting and post-transplant diabetes mellitus on outcomes following liver transplantation.","volume":"103","author":"Aravinthan","year":"2019","journal-title":"Transplantation"},{"key":"R153-20250607","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.transproceed.2019.04.030","article-title":"Risk factors associated with new-onset diabetes after liver transplant: a case control study.","volume":"51","author":"Terto","year":"2019","journal-title":"Transplant Proc"},{"key":"R154-20250607","doi-asserted-by":"crossref","first-page":"e23192","DOI":"10.1002\/jcla.23192","article-title":"A retrospective cohort study of preoperative lipid indices and their impact on new-onset diabetes after liver transplantation.","volume":"34","author":"Liang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"R155-20250607","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1097\/TP.0000000000002811","article-title":"Body weight parameters are related to morbidity and mortality after liver transplantation: a systematic review and meta-analysis.","volume":"103","author":"Beckmann","year":"2019","journal-title":"Transplantation"},{"key":"R156-20250607","doi-asserted-by":"crossref","first-page":"e13554","DOI":"10.1111\/ctr.13554","article-title":"The impact of post-transplant diabetes mellitus on liver transplant outcomes.","volume":"33","author":"Lieber","year":"2019","journal-title":"Clin Transplant"},{"key":"R157-20250607","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12876-015-0407-y","article-title":"Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis.","volume":"15","author":"Stepanova","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"R158-20250607","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"R159-20250607","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R160-20250607","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1432-2277.2008.00804.x","article-title":"New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies.","volume":"22","author":"Chen","year":"2009","journal-title":"Transpl Int"},{"key":"R161-20250607","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/dom.14168","article-title":"Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study.","volume":"22","author":"Adinolfi","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R162-20250607","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciz304","article-title":"Hepatitis C virus (HCV) treatment with directly acting agents reduces the risk of incident diabetes: results from Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).","volume":"70","author":"Butt","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R163-20250607","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/lt.25351","article-title":"Sustained virological response is associated with a decreased risk of posttransplant diabetes mellitus in liver transplant recipients with hepatitis C-related liver disease.","volume":"24","author":"Roccaro","year":"2018","journal-title":"Liver Transpl"},{"key":"R164-20250607","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/liv.13042","article-title":"New-onset diabetes after liver transplantation: a national report from China Liver Transplant Registry.","volume":"36","author":"Ling","year":"2016","journal-title":"Liver Int"},{"key":"R165-20250607","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1007\/s00125-004-1499-z","article-title":"Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation.","volume":"47","author":"Hjelmesaeth","year":"2004","journal-title":"Diabetologia"},{"key":"R166-20250607","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/meta.2003.50092","article-title":"Determinants of insulin secretion after renal transplantation.","volume":"52","author":"Hjelmesaeth","year":"2003","journal-title":"Metabolism"},{"key":"R167-20250607","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.transproceed.2011.05.050","article-title":"The influence of cytomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study).","volume":"43","author":"Abou-Ayache","year":"2011","journal-title":"Transplant Proc"},{"key":"R168-20250607","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/tri.13145","article-title":"Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk\u2014an observational, retrospective study.","volume":"31","author":"Aguilera","year":"2018","journal-title":"Transpl Int"},{"key":"R169-20250607","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1177\/00912700122012733","article-title":"Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race.","volume":"41","author":"Magee","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R170-20250607","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MAJ.0b013e31828a6a01","article-title":"Glucocorticoid-induced hyperglycemia.","volume":"345","author":"Kwon","year":"2013","journal-title":"Am J Med Sci"},{"key":"R171-20250607","doi-asserted-by":"crossref","first-page":"e0160421","DOI":"10.1371\/journal.pone.0160421","article-title":"Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant.","volume":"11","author":"Muduma","year":"2016","journal-title":"PLoS One"},{"key":"R172-20250607","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"R173-20250607","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1476-5381.2010.01018.x","article-title":"Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.","volume":"162","author":"\u00d8zbay","year":"2011","journal-title":"Br J Pharmacol"},{"key":"R174-20250607","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2337\/diab.35.9.1049","article-title":"Direct effects of cyclosporin A on human pancreatic beta-cells.","volume":"35","author":"Nielsen","year":"1986","journal-title":"Diabetes"},{"key":"R175-20250607","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/00007890-199908150-00012","article-title":"Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation.","volume":"68","author":"Drachenberg","year":"1999","journal-title":"Transplantation"},{"key":"R176-20250607","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1600-6143.2009.02752.x","article-title":"Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation.","volume":"9","author":"Van Laecke","year":"2009","journal-title":"Am J Transplant"},{"key":"R177-20250607","doi-asserted-by":"crossref","first-page":"e14316","DOI":"10.14814\/phy2.14316","article-title":"Tacrolimus-induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin.","volume":"8","author":"Gratreak","year":"2020","journal-title":"Physiol Rep"},{"key":"R178-20250607","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2362.2008.01957.x","article-title":"Hypomagnesaemia and risk for metabolic glucose disorders: a 10-year follow-up study.","volume":"38","author":"Guerrero-Romero","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"R179-20250607","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/TP.0b013e31822d880d","article-title":"Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial.","volume":"92","author":"Schmeding","year":"2011","journal-title":"Transplantation"},{"key":"R180-20250607","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2147\/TCRM.S142348","article-title":"Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients.","volume":"13","author":"Liu","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"R181-20250607","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1097\/TP.0000000000001228","article-title":"Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study.","volume":"100","author":"Saliba","year":"2016","journal-title":"Transplantation"},{"key":"R182-20250607","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/petr.12362","article-title":"Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies.","volume":"18","author":"Crins","year":"2014","journal-title":"Pediatr Transplant"},{"key":"R183-20250607","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1499-3872(16)60183-2","article-title":"Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials.","volume":"16","author":"Zhang","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R184-20250607","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.hpb.2020.09.012","article-title":"Randomized trial of steroid free immunosuppression with basiliximab induction in adult live donor liver transplantation (LDLT).","volume":"23","author":"Kathirvel","year":"2021","journal-title":"HPB (Oxford)"},{"key":"R185-20250607","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/jdi.12560","article-title":"Donor liver steatosis: a risk factor for early new-onset diabetes after liver transplantation.","volume":"8","author":"Xue","year":"2017","journal-title":"J Diabetes Investig"},{"key":"R186-20250607","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6002\/ect.2019.0168","article-title":"Comorbidities and age in brain-dead donors and liver transplantation: a 15-year retrospective investigation.","volume":"18","author":"Lazzeri","year":"2020","journal-title":"Exp Clin Transplant"},{"key":"R187-20250607","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/liv.12706","article-title":"Early occurrence of new-onset diabetes after transplantation is related to type of liver graft and warm ischaemic injury.","volume":"35","author":"Hartog","year":"2015","journal-title":"Liver Int"},{"key":"R188-20250607","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.gene.2017.06.060","article-title":"Association of donor and recipient SUMO4 rs237025 genetic variant with new-onset diabetes mellitus after liver transplantation in a Chinese population.","volume":"627","author":"Zhang","year":"2017","journal-title":"Gene"},{"key":"R189-20250607","doi-asserted-by":"crossref","first-page":"e22308","DOI":"10.1002\/jcla.22308","article-title":"Multiple genetic variants associated with posttransplantation diabetes mellitus in Chinese Han populations.","volume":"32","author":"Chen","year":"2018","journal-title":"J Clin Lab Anal"},{"key":"R190-20250607","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.transproceed.2019.03.027","article-title":"SNPs within the MTOR gene are associated with an increased risk of developing de novo diabetes mellitus following the administration of everolimus in liver transplant recipients.","volume":"51","author":"Husen","year":"2019","journal-title":"Transplant Proc"},{"key":"R191-20250607","first-page":"137","article-title":"Evaluation of angiotensinogen M235T and T174M polymorphisms, demographic and clinical factors in new-onset diabetes after liver transplantation in Iranian patients.","volume":"10","author":"Mottaghi","year":"2019","journal-title":"Int J Organ Transplant Med"},{"key":"R192-20250607","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1499-3872(17)60069-9","article-title":"Association between ADIPOQ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation.","volume":"16","author":"Cen","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R193-20250607","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.trre.2016.09.001","article-title":"Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus.","volume":"31","author":"Vanhove","year":"2017","journal-title":"Transplant Rev (Orlando)"},{"key":"R194-20250607","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/TP.0b013e31822e0bee","article-title":"Body composition and overweight of liver transplant recipients.","volume":"92","author":"Anast\u00e1cio","year":"2011","journal-title":"Transplantation"},{"key":"R195-20250607","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.3390\/nu11123015","article-title":"Weight gain and de novo metabolic disorders after liver transplantation.","volume":"11","author":"Lattanzi","year":"2019","journal-title":"Nutrients"},{"key":"R196-20250607","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/1747-0080.12548","article-title":"\u2018Back to Life\u2019\u2014using knowledge exchange processes to enhance lifestyle interventions for liver transplant recipients: a qualitative study.","volume":"76","author":"Hickman","year":"2019","journal-title":"Nutr Diet"},{"key":"R197-20250607","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/TP.0000000000002317","article-title":"Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation.","volume":"103","author":"Narayanan","year":"2019","journal-title":"Transplantation"},{"key":"R198-20250607","doi-asserted-by":"crossref","first-page":"389","DOI":"10.12659\/AOT.890664","article-title":"Thiazolidinedione therapy versus lifestyle recommendation in the treatment of post-liver transplant graft steatosis.","volume":"19","author":"\u00c5berg","year":"2014","journal-title":"Ann Transplant"},{"key":"R199-20250607","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/1357633X19900459","article-title":"Liver transplant recipients\u2019 experiences and perspectives of a telehealth-delivered lifestyle programme: a qualitative study.","volume":"27","author":"Barnett","year":"2021","journal-title":"J Telemed Telecare"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T12:14:32Z","timestamp":1749298472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":197,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003867","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,23]]}}}